Eastern canadian colorectal cancer consensus conference 2017

S. F. McGee, W. Alghareeb, C. H. Ahmad, D. Armstrong, S. Babak, S. Berry, J. Biagi, C. Booth, D. Bossé, P. Champion, B. Colwell, N. Finn, R. Goel, S. Gray, J. Green, M. Harb, A. Hyde, A. Jeyakumar, D. Jonker, S. KanagaratnamP. Kavan, A. Macmillan, A. Muinuddin, N. Patil, G. Porter, E. Powell, R. Ramjeesingh, M. Raza, S. Rorke, M. Seal, F. Servidio-Italiano, J. Siddiqui, J. Simms, L. Smithson, S. Snow, E. St-Hilaire, T. Stuckless, A. Tate, M. Tehfe, M. Thirlwell, E. Tsvetkova, M. Valdes, M. Vickers, K. Virik, S. Welch, C. Marginean, Timothy Asmis, Dawson, Mahmud

Résultat de recherche: Articleexamen par les pairs

5 Citations (Scopus)

Résumé

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2017 was held in St. John’s, Newfoundland and Labrador, 28–30 September. Experts in radiation oncology, medical oncology, surgical oncology, and cancer genetics who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of gastric, rectal, and colon cancer, including identification and management of hereditary gastric and colorectal cancer (CRC); palliative systemic therapy for metastatic gastric cancer; optimum duration of preoperative radiation in rectal cancer—that is, short-compared with long-course radiation; management options for peritoneal carcinomatosis in CRC; implications of tumour location for treatment and prognosis in CRC; and new molecular markers in CRC.

Langue d'origineEnglish
Pages (de-à)262-274
Nombre de pages13
JournalCurrent Oncology
Volume25
Numéro de publication4
DOI
Statut de publicationPublished - août 2018

Note bibliographique

Funding Information:
We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: DA is a member of advisory boards for Celgene and Shire, and has received grants or honoraria from Celgene and Amgen. TA is a member of advisory boards for Amgen, Novartis, Ipsen, Celgene, and Shire, and has received grants or honoraria from Novartis, Roche, and Boehringer Ingelheim. SB is a member of advisory boards for Eli Lilly and Amgen. PC was a one-time advisory board member for AstraZeneca and Merck in 2017, Pfizer and Eli Lilly in 2016, and Celgene, Sanofi, and Boehringer Ingelheim in 2015. BC is a member of advisory boards for Celgene and Novartis, and a member of a speakers bureau for Novartis. SG is a member of advisory boards for Bayer, Roche, Pfizer, Astellas, and Novartis, and her institution has received funding from Bristol–Myers Squibb and Amgen for a clinical trial in which she is listed as an investigator. JG has received grants and honoraria from Novartis. MH is a member of advisory boards for Amgen, Roche, Novartis, Celgene, and Pfizer, and has received grants or honoraria from Novartis and Astellas. DJ’s institution has received funding from AstraZeneca, Bristol–Myers Squibb, Roche, Esperas, Pfizer, Corvus, Turnstone Biologics, Merck, Boston Biomedical, and Array, for clinical trials in which he is listed as an investigator. PK has received grants or honoraria from Pfizer, Celgene, and Shire. EP is a member of advisory boards for Amgen, Novartis, and Genomic Health, and has received grants and honoraria from Roche. RR is a member of a speakers bureau for Astellas, Merck, Roche, Eli Lilly, AstraZeneca, and Bristol–Myers Squibb, and has received grants or honoraria from Celgene, Amgen, and Novartis. MR is a member of advisory boards for, and has received grants or honoraria from, Jensen and Novartis. MS is a member of advisory boards for Shire and Pfizer, and has received grants and honoraria from Amgen. LS is a member of the American College of Surgeons Rural Surgery Advisory Counsel. ESH is a member of advisory boards for Celgene, Bristol–Myers Squibb, Novartis, and Merck.

Publisher Copyright:
© 2018 Multimed Inc.

ASJC Scopus Subject Areas

  • Oncology

Empreinte numérique

Plonger dans les sujets de recherche 'Eastern canadian colorectal cancer consensus conference 2017'. Ensemble, ils forment une empreinte numérique unique.

Citer